Investing.com — Shares in Biogen (NASDAQ:BIIB) were trading marginally higher after the company said its investigational antibody felzartamab had received...
Read moreNEW DELHI (Reuters) – Ratan Tata, the chairman emeritus of one of India’s biggest conglomerates, Tata Sons, is in critical...
Read moreInvesting.com – Saudi Arabia stocks were lower after the close on Wednesday, as losses in the Insurance, Energy & Utilities...
Read moreInvesting.com — Ahead of its third-quarter earnings report scheduled for October 23rd, IBM (NYSE:IBM) has gained new Street high price...
Read more(Reuters) – Honda (NYSE:HMC) is recalling about 1.7 million vehicles in the U.S. as difficulty in steering on certain models...
Read more(Reuters) – Stock index futures fell on Wednesday as investors awaited the release of minutes from the Federal Reserve’s last...
Read moreLONDON (Reuters) – Hurricane Milton could result in a $60 billion loss for the global insurance industry, creating a surge...
Read moreA look at the day ahead in U.S. and global markets from Mike Dolan Wall St stocks roared back on...
Read moreInvesting.com — HSBC analysts see room for S&P 500 earnings to outperform expectations in Q3, given the low forecasts heading into...
Read moreInvesting.com – India stocks were lower after the close on Wednesday, as losses in the Fast Moving Consumer Goods, Healthcare...
Read moreDisclaimer: WallStreetJedi.com, its managers, its employees, and assigns (collectively "The Company") do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.